American Association for Cancer Research Archives

Representative image of live tumour profiling and cytotoxicity testing, illustrating how the Elephas elive platform could expand functional precision oncology beyond immunotherapy into targeted therapy response assessment. Representative image.

Can Elephas move beyond immunotherapy? New elive data opens a targeted therapy pathway

by Pallavi Madhiraju
July 25, 2026
0 Comments

Elephas reports early elive data showing cytotoxicity measurement with daraxonrasib, expanding live tumor profiling beyond immunotherapy.

Pheast Therapeutics’ PHST001 anti-CD24 research highlights a macrophage-directed approach to targeting solid tumors as Phase 1 combination testing advances. Representative image.

Pharma & Biotech

Pheast Therapeutics strengthens PHST001 case with peer-reviewed anti-CD24 cancer research

by Pallavi Madhiraju
July 22, 2026
0 Comments

Pheast Therapeutics’ PHST001 gains peer-reviewed CD24 data as Phase 1 combination cohorts advance. See what the evidence means.

Tract Bio’s TP101 and stemECHO research targets drug-resistant cancer stem cells through preclinical combination testing and functional precision medicine screening. Representative image.

Pharma & Biotech

TP101 drove near-complete tumor regression in mice. What must Tract Bio prove next?

by Pallavi Madhiraju
July 22, 2026
0 Comments

Tract Bio's AACR posters link TP101 and stemECHO to drug-resistant cancer stem cells, while IND work and clinical validation remain the key hurdles ahead.